Nektar Therapeutics Stock Analysis
| NKTR Stock | USD 0.86 0.01 1.15% |
Nektar Therapeutics is overvalued with Real Value of 0.75 and Hype Value of 0.86. The main objective of Nektar Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Nektar Therapeutics is worth, separate from its market price. There are two main types of Nektar Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Nektar Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Nektar Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Nektar Stock trading window is adjusted to America/New York timezone.
Nektar |
Nektar Stock Analysis Notes
About 72.0% of the company shares are owned by institutional investors. The book value of Nektar Therapeutics was now reported as 0.33. The company recorded a loss per share of 0.58. Nektar Therapeutics had not issued any dividends in recent years. The entity had 2:1 split on the 23rd of August 2000. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Nektar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. To find out more about Nektar Therapeutics contact Howard Robin at 415 482 5300 or learn more at https://www.nektar.com.Nektar Therapeutics Investment Alerts
| Nektar Therapeutics had very high historical volatility over the last 90 days | |
| Nektar Therapeutics has some characteristics of a very speculative penny stock | |
| Nektar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 98.43 M. Net Loss for the year was (118.96 M) with profit before overhead, payroll, taxes, and interest of 67.74 M. | |
| Nektar Therapeutics currently holds about 546.39 M in cash with (175.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 72.0% of the company shares are owned by institutional investors |
Nektar Therapeutics Upcoming and Recent Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Nektar Therapeutics Thematic Classifications
In addition to having Nektar Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Trump EquitiesCompanies that have responded positively to Trump presidency |
Nektar Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 160.74 M.Nektar Profitablity
The company has Profit Margin (PM) of (1.21) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.85) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.85.Technical Drivers
As of the 24th of March, Nektar Therapeutics secures the Mean Deviation of 3.99, risk adjusted performance of 0.0128, and Downside Deviation of 5.11. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nektar Therapeutics, as well as the relationship between them. Please verify Nektar Therapeutics coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Nektar Therapeutics is priced some-what accurately, providing market reflects its recent price of 0.86 per share. Given that Nektar Therapeutics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.Nektar Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Nektar Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Nektar Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Nektar Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nektar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nektar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nektar Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nektar Therapeutics Outstanding Bonds
Nektar Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nektar Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nektar bonds can be classified according to their maturity, which is the date when Nektar Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Nektar Therapeutics Predictive Daily Indicators
Nektar Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Nektar Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 172344.0 | |||
| Daily Balance Of Power | (0.10) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 0.87 | |||
| Day Typical Price | 0.87 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) |
Nektar Therapeutics Forecast Models
Nektar Therapeutics' time-series forecasting models are one of many Nektar Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nektar Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Nektar Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Nektar Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nektar shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nektar Therapeutics. By using and applying Nektar Stock analysis, traders can create a robust methodology for identifying Nektar entry and exit points for their positions.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Nektar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Nektar Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.